Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

Fineline Cube Mar 2, 2026
Company Drug

HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline

Fineline Cube Mar 2, 2026
Company

Sichuan Kelun Pharmaceutical Reports 12.69% YOY Revenue Growth in 2023 Financial Results

Fineline Cube Apr 25, 2024

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a leading pharmaceutical company in China, has announced...

Policy / Regulatory

China Unveils 16-Measure Policy to Support Overseas Investment in Domestic Tech Firms

Fineline Cube Apr 24, 2024

A coalition of 10 Chinese government bureaus, including the Ministry of Commerce, Ministry of Foreign...

Company Drug

Sanofi’s Rilzabrutinib Meets Primary Endpoint in Phase III ITP Trial

Fineline Cube Apr 24, 2024

French pharmaceutical company Sanofi (NASDAQ: SNY) has announced that its Phase III trial for rilzabrutinib,...

Policy / Regulatory

China’s CSRC Unveils 16 Measures to Boost Capital Market and Tech Enterprises

Fineline Cube Apr 24, 2024

The China Securities Regulatory Commission (CSRC) has introduced a comprehensive set of 16 measures aimed...

Company

Novartis Reports 11% YOY Sales Growth in Q1 2024, Led by Entresto and Cosentyx

Fineline Cube Apr 24, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has reported an 11% year-on-year (YOY) increase in constant...

Company

Lepu Medical Technology Reports 2023 Revenues of RMB 7.98 Billion, Marking a 24.78% YOY Decrease

Fineline Cube Apr 24, 2024

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has released...

Company Drug

European Commission Approves Pfizer’s Antibiotic Emblaveo for Multiple Indications

Fineline Cube Apr 24, 2024

The European Commission (EC) has granted approval for Pfizer’s (NYSE: PFE) antibiotic Emblaveo (aztreonam +...

Company Drug

BeiGene’s Tislelizumab Secures EC Approval for Three NSCLC Indications

Fineline Cube Apr 24, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that the European Committee (EC) has...

Company Drug

Shanghai Henlius Biotech Achieves First Patient Dosing in Phase I Trial for Fibrosis Treatment HLX6018

Fineline Cube Apr 24, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a biopharmaceutical company based in China, has announced the...

Policy / Regulatory

China’s Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value

Fineline Cube Apr 24, 2024

The renewal of winning bids from the insulin volume-based procurement (VBP) tender, initially held in...

Company Drug

China Medical System Holdings’ Desidustat NDA Accepted for Review by China’s NMPA

Fineline Cube Apr 24, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that the National Medical Products Administration...

Company Drug

Akeso Biopharma Submits sNDA for Cadonilimab in Cervical Cancer to China’s CDE

Fineline Cube Apr 24, 2024

China-based Akeso Biopharma (HKG: 9926) has announced the submission of a supplementary New Drug Application...

Company Drug

Huadong Medicine’s HDM1005 Receives US FDA Clinical Trial Approval for Weight Management

Fineline Cube Apr 23, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clinical trial...

Company Drug

Sandoz’s Partner Samsung Bioepis Scores EC Approval for Stelara Biosimilar Pyzchiva

Fineline Cube Apr 23, 2024

Switzerland-headquartered Sandoz (SWX: SDZ) has announced that the European Commission (EC) has granted approval for...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Go-Ahead for Camrelizumab Combination Therapy Study in Pancreatic Cancer

Fineline Cube Apr 23, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Deals

Zhejiang Dian Diagnostics Partners with Henan Institute to Open Neuroimmunity Research Center

Fineline Cube Apr 23, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a medical diagnostics company based in China, has...

Company Drug

CanSino Biologics Receives NMPA Approval for Haemophilus influenzae type B (Hib) Conjugate Vaccine Clinical Trial

Fineline Cube Apr 23, 2024

China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced that it has received clinical trial...

Company Drug

CANbridge Pharmaceuticals’ CAN008 Fails to Meet Phase II Endpoints in Glioblastoma Multiforme

Fineline Cube Apr 23, 2024

CANbridge Pharmaceuticals (HKG: 1228) has announced that its Phase II clinical study for CAN008 (asunercept)...

Company Deals R&D

Shenzhen Wingor Biotechnology Partners with Guangzhou Institute of Respiratory Health for MSC Exos Research

Fineline Cube Apr 23, 2024

Shenzhen Wingor Biotechnology Co., Ltd, a Chinese biotechnology company, has entered into a scientific research...

Company Deals

Kingmed Diagnostics Partners with GenStar Biosolutions to Develop Auto-Antibody Immunofluorescence AI Software

Fineline Cube Apr 23, 2024

Kingmed Diagnostics, a leading independent medical laboratory based in Guangdong, has entered into a strategic...

Posts pagination

1 … 333 334 335 … 628

Recent updates

  • Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy
  • HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline
  • Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug
  • GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC
  • InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

Company Drug

HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline

Company Drug

Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug

Company Drug

GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.